Pediatric liver transplant portal vein anastomotic stenosis: Correlation between ultrasound and transhepatic portal venography

C. Matthew Hawkins, Dennis W. W. Shaw, Patrick J. Healey, Simon P. Horslen, Andre A. S. Dick, Seth Friedman, Giridhar M. Shivaram – 3 February 2015 – The objective of this study was to determine which transabdominal ultrasound parameters correlate with portal vein stenosis (PVS) on percutaneous transhepatic portal venography in pediatric liver transplant patients. A retrospective review was performed of percutaneous transhepatic portal venograms performed between 2005 and 2013. The findings were compared to those from ultrasounds performed before venography and at the baseline.

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

Massimo Iavarone, Giuseppe Cabibbo, Marco Biolato, Cristina Della Corte, Marcello Maida, Marco Barbara, Michele Basso, Sara Vavassori, Antonio Craxì, Antonio Grieco, Carlo Cammà, Massimo Colombo – 2 February 2015 – Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects.

Differentiation of acute from chronic hepatitis C virus infection by nonstructural 5B deep sequencing: A population‐level tool for incidence estimation

Vincent Montoya, Andrea D. Olmstead, Naveed Z. Janjua, Patrick Tang, Jason Grebely, Darrel Cook, P. Richard Harrigan, Mel Krajden – 2 February 2015 – The ability to classify acute versus chronic hepatitis C virus (HCV) infections at the time of diagnosis is desirable to improve the quality of surveillance information. The aim of this study was to differentiate acute from chronic HCV infections utilizing deep sequencing.

DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma

Augusto Villanueva, Anna Portela, Sergi Sayols, Carlo Battiston, Yujin Hoshida, Jesús Méndez‐González, Sandrine Imbeaud, Eric Letouzé, Virginia Hernandez‐Gea, Helena Cornella, Roser Pinyol, Manel Solé, Josep Fuster, Jessica Zucman‐Rossi, Vincenzo Mazzaferro, Manel Esteller, Josep M. Llovet, on behalf of the HEPTROMIC Consortium – 2 February 2015 – Epigenetic deregulation has emerged as a driver in human malignancies. There is no clear understanding of the epigenetic alterations in hepatocellular carcinoma (HCC) and of the potential role of DNA methylation markers as prognostic biomarkers.

Impact of elderly donors for liver transplantation: A single‐center experience

Naoko Kamo, Toshimi Kaido, Ahmed Hammad, Kohei Ogawa, Yasuhiro Fujimoto, Tadahiro Uemura, Akira Mori, Etsuro Hatano, Hideaki Okajima, Shinji Uemoto – 31 January 2015 – Elderly donor grafts for liver transplantation (LT) are recognized to be marginal grafts. The present study investigated the impact of using elderly donors for LT. Between June 1990 and August 2012, 1631 patients received LT at Kyoto University Hospital. Out of 1631 patients, 1597 patients received living donor liver transplantation (LDLT), whereas the other 34 patients underwent deceased donor liver transplantation (DDLT).

[18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco‐ablative therapies for hepatocellular carcinoma

Yael Asman, Amy R. Evenson, Einat Even‐Sapir, Oren Shibolet – 31 January 2015 – Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer‐related death worldwide. Orthotopic liver transplantation (OLT) and resection are curative treatment options for well‐selected patients with HCC, whereas loco‐ablative therapy has been shown to prolong survival.

Subscribe to